OralParenteralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Urea

CAS 57-13-6

Urea (CAS 57-13-6) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 691 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
691
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Urea
CAS Number
57-13-6
UNII
8W8T17847W
InChIKey
XSQUKJJJFZCRTK-UHFFFAOYSA-N
ChEMBL ID
CHEMBL985
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural productoralparenteraltherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL985 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 54494.65555555556 nM 9 -
- IC50 19976.309999999998 nM 1 -
- EC50 23 nM 1 -
Olfactory receptor 51E2
GPCR
 EC50 7.64 - Homo sapiens
SOURCE DrugCentral 14 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Palmar-plantar erythrodysaesthesia syndrome 82 220.038 10033553
Decreased appetite 95 68.926 10061428
Hypertension 86 54.827 10020772
Hepatic function abnormal 35 44.092 10019670
Platelet count decreased 54 39.977 10035528
Hepatic encephalopathy 21 37.996 10019660
Hypercholesterolaemia 20 32.378 10020603
Diarrhoea 121 28.445 10012735
Blood bilirubin increased 26 27.762 10005364
Hepatocellular carcinoma 12 25.86 10073071
Colon cancer 14 24.438 10009944
Dermatitis exfoliative 12 24.35 10012455
Enterocolitis 13 23.654 10014893
C-reactive protein increased 32 20.936 10006825

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
solute carrier family 60 member 2
Mfsd4b4
 Inhibition - 26423860
SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
UREA 11002 SU MTHSPL
Urea 11002 SU MTHSPL
urea 11002 SU MTHSPL
urea 11002 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Urea used for in pharmaceutical contexts?

Urea (CAS 57-13-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Urea?

Urea has 691 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Palmar-plantar erythrodysaesthesia syndrome, Decreased appetite, Hypertension, Hepatic function abnormal, Platelet count decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Urea also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Urea with EU status "permitted".

What clinical phase is Urea in?

Urea is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Urea?

Urea has 4 bioactivity rows in this page query. Rendered target entries include Olfactory receptor 51E2.